Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TachoSil vs standard surgical treatment for intra-operative pulmonary air leakage after lobectomy
2004-002380-24Phase 3Completed
- Sponsor
- Nycomed
- Start
- Nov 2005
- Modality
- Recombinant Proteins and Enzymes, Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tachosil in bronchial carcinoma, lung metastases (LM) and air-leak syndrome (2 arms), sponsored by Nycomed. Primary endpoint: Duration of post-operative air leakage. Started Nov 2005; status: completed.
02
Drugs
tachosil
03
Conditions
bronchial carcinomalung metastases (LM)air-leak syndrome
Beyond the preview
Go deeper on 2004-002380-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002380-24.